AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27324337
Drug: non-opioid/opioid analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-opioid/opioid analgesic combinations plus topical 0.25% bupivacaine onto the cystic plate and local 0.25% bupivacaine port-site injection
Trial: 26445140
Drug: Mepolizumab 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 75 mg IV
Trial: 26445140
Drug: Mepolizumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab SC doses providing 50% inhibition
Trial: 11742962
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily T‐piece weaning or pressure support
Trial: 29673465
Drug: Ibuprofen with
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen with aspirin
Trial: 20799399
Drug: Immunovac‐VP4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunovac‐VP4 vaccine
Trial: 18388929
Drug: NV1FGF (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NV1FGF (2.5 ml at 0.2 mg/ml, 8 intramuscular injections on days 1, 15, 30, and 45)
Trial: 10727077
Drug: Vitamin antioxidant
RxNorm normalized name: Glucosamine/Chondroitin Sulfate A/Multivitamin Antioxidant 5 400 mg-300 mg-425 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin antioxidant mixture (600 mg alpha‐tocopherol, 1,000 mg vitamin C, 32 mg beta‐carotene)
Trial: 1510435
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of ceftazidime (1-g dose)
Trial: 1510435
Drug: Endotracheal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal administration of ceftazidime (1-g dose)
Trial: 1510435
Drug: Aerosol administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol administration of ceftazidime (1-g dose)
Trial: 20197487
Drug: 350 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg, 700 mg, 1400 mg, or 2100 mg of artemisinin-naphthoquine phosphate
Trial: 20197487
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of artemisinin and naphthoquine phosphate
Trial: 20197487
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration
Trial: 17905357
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken twice daily for 12 weeks
Trial: 11905547
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide 200 microg metered dose inhaler (MDI) administered by Fluspacer
Trial: 2146282
Drug: DHEA (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (1600 mg/day, orally)
Trial: 31757
Drug: Morphine anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine anaesthesia (4 mg/kg before skin incision)
Trial: 31499206
Drug: Single-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rifampicin (SDR) after BCG vaccination
Trial: 20101064
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg intact capsules under fasting conditions
Trial: 10099127
Drug: Oral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunization
Trial: 23671895
Drug: Amitriptyline 10mg
RxNorm normalized name: amitriptyline 10 MG
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline 10mg daily
Trial: 23671895
Drug: Amitriptyline 10mg
RxNorm normalized name: amitriptyline 10 MG
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline 10mg daily with Pindolol 5mg twice daily
Trial: 23671895
Drug: Surrogate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrogate placebo (Loratadine 10mg daily)
Trial: 17353873
Drug: New compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New compounds targeting androgen receptors
Trial: 10383560
Drug: Oxymetazoline nasal
RxNorm normalized name: oxymetazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline nasal spray (0.9 mg)
Trial: 12074329
Drug: FHIG (infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FHIG (infusional fluorouracil 2.6 g/m2 over 24 hours once per week for 6 weeks, infusional hydroxyurea 4.3 g/m2 over 24 hours once per week for 6 weeks, interferon-alpha-2a 9 MU subcutaneously three times per week for 6 weeks)
Trial: 12074329
Drug: AD (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 intravenously every 21 days)
Trial: 8961505
Drug: rhGM-CSF (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF (20-40 micrograms, injected at the same site as the vaccine)
Trial: 29696357
Drug: Post-acute assessment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-acute assessment (8 weeks after first in-patient treatment)
Trial: 17556408
Drug: TAK-044 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-044 (100 mg)
Trial: 14736774
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of latanoprost 0.005% and timolol 0.5% (once daily morning dose)
Trial: 14736774
Drug: Unfixed combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfixed combination of latanoprost 0.005% (once daily evening) and timolol 0.5% (twice daily)
Trial: 11910258
Drug: Fluoxetine, Sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, Sertraline, Paroxetine
Trial: 1388702
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 ml NaCl)
Trial: 26485501
Drug: Complete device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete device removal and antibiotic treatment for six weeks
Trial: 11942883
Drug: Hydralazine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (5-10 mg intravenous)
Trial: 132705
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline preparation
Trial: 132705
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline 0.5 gm daily
Trial: 15696244
Drug: Edifoligide (E2F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edifoligide (E2F Decoy) administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation.
Trial: 10547465
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus radiation
Trial: 31596491
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure target < 120 mm Hg)
Trial: 31596491
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure target < 140 mm Hg)
Trial: 24637999
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (C2 to C22)
Trial: 24637999
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (C2 to C6) plus placebo (C7 to C22)
Trial: 24637999
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus placebo (C2 to C22)
Trial: 17627173
Drug: IM injection
RxNorm normalized name: filgrastim Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection of 40 mg piroxicam
Trial: 17627173
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg piroxicam FDDF sublingual tablets
Trial: 22220766
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg followed by 250 mg 24 hours later
Trial: 15040643
Drug: Zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 600 mg once/day
Trial: 8002329
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of sublingual apomorphine
Trial: 7802151
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (AP): alfentanil 30 micrograms/kg and propofol 1.5 mg/kg
Trial: 7802151
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (SE): sufentanil 0.3 microgram/kg and etomidate 0.3 mg/kg
Trial: 7802151
Drug: Group IV
RxNorm normalized name: Corticosteroids, very potent (group IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV (SP): sufentanil 0.3 microgram/kg and propofol 1.5 mg/kg
Trial: 28486629
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with ropivacaine 0.15%, 1.5 ml kg ‐1 (High-Volume group)
Trial: 28486629
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with ropivacaine 0.15%, 1.0 ml kg ‐1 (Low-Volume group)
Trial: 26419732
Drug: Anticholinergic medication
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic medication exposure
Trial: 21160054
Drug: Applied behaviour
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied behaviour analysis by a specialist team plus standard treatment
Trial: 11308049
Drug: rhGH (Genotropin)
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (Genotropin) at a dose of 0.2 IU/kg/day as daily s.c. injections for two years
Trial: 7950213
Drug: Single-blind treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blind treatment with EF
Trial: 31229401
Drug: Deferasirox and
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox and deferoxamine combination (30 mg/kg deferasirox daily plus SC 50 mg/kg deferoxamine for 5 days a week)
Trial: 25405276
Drug: Fentanyl (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (200 μg before ERCP)
Trial: 25405276
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal placebo before ERCP and placebo during ERCP)
Trial: 23234763
Drug: Lapatinib (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1500 mg daily for 12 months)
Trial: 12091295
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (100 microg four times daily for 10 days via Aerochamber)
Trial: 20705782
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of lidocaine 2% 30 mL
Trial: 20705782
Drug: Triple injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple injection adjacent to each brachial plexus cord
Trial: 16255952
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of NPPV plus standard medical treatment (group B)
Trial: 10088941
Drug: Oxaceprol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaceprol (200 mg three times daily)
Trial: 10088941
Drug: Diclofenac (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (25 mg three times daily)
Trial: 7562088
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (30 g/d)
Trial: 7562088
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alcohol treatment (energy replaced with carbohydrate)
Trial: 1705137
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg three times daily)
Trial: 1705137
Drug: Toloxatone (400-200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toloxatone (400-200-400 mg day-1)
Trial: 6450544
Drug: Oxygen/nitrous oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen/nitrous oxide sedation (relative analgesia) with diazepam premedication 0.2 mg/kg
Trial: 31134784
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy training for 8 weeks, 16 sessions, combined with conventional therapy 5 days a week
Trial: 23165381
Drug: Intranasal theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal theophylline methylpropyl paraben, 20 μg/d in each naris for 4 weeks
Trial: 17437343
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral calcium and vitamin D supplementation starting on postoperative day 1
Trial: 17437343
Drug: No routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No routine oral calcium and vitamin D supplementation
Trial: 11865132
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (9-30 mg; mean dosage 16 mg)
Trial: 1377036
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (total greater than 5 x 10(6) kallikrein inactivator units [KIU])
Trial: 1377036
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aprotinin administration)
Trial: 6714602
Drug: New solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New solution containing mainly sodium sulfate and polyethylene glycol (solution II)
Trial: 6714602
Drug: Balanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced standard electrolyte solution (solution I)
Trial: 31375087
Drug: Rituximab (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (two 375 mg/m2 doses, maximum dose: 500 mg)
Trial: 29468764
Drug: Hesperidin 500
RxNorm normalized name: Ascorbic Acid/Bioflavonoid/Hesperidin 500 MG-100 MG-100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hesperidin 500 mg/day
Trial: 19854713
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral DHEA
Trial: 10948809
Drug: Antihistamine nasal
RxNorm normalized name: Antihistamine Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine nasal spray (azelastine hydrochloride)
Trial: 3542982
Drug: Oral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of fluphenazine hydrochloride
Trial: 29504794
Drug: Emotion Regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion Regulation Therapy (ERT)
Trial: 24385117
Drug: luliconazole cream
RxNorm normalized name: Luliconazole Cream
DrugBank: Luliconazole (DB08933)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: luliconazole cream 1%
Trial: 15189367
Drug: Alfacalcidol 0.25
RxNorm normalized name: alfacalcidol 0.25 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Trial: 7658310
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 300 U/kg rhEPO in healthy non-pregnant volunteers
Trial: 2487544
Drug: naloxone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (0.2 mg/kg) infusion
Trial: 22120829
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion
Trial: 30445841
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (losartan plus lisinopril)
Trial: 30445841
Drug: Monotherapy (losartan)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (losartan)
Trial: 22620494
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI), 300 mg twice daily for 28 days
Trial: 18266876
Drug: Implant-supported mandibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported mandibular overdentures (n=49)
Trial: 8612390
Drug: Tacrine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (40 mg) alone
Trial: 1597980
Drug: Warm control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm control patients (no drug)
Trial: 1597980
Drug: Cold control
RxNorm normalized name: Acetaminophen/Diphenhydramine Hydrochloride/Phenylephrine Hydrochloride 650 MG-25 MG-10 MG Oral Tablet [COLD CONTROL PE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold control patients (no drug; n = 20)
Trial: 6338768
Drug: Ocular decongestant
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular decongestant product 1 (naphazoline hydrochloride + antazoline phosphate)
Trial: 6338768
Drug: Ocular decongestant
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular decongestant product 2 (naphazoline hydrochloride + pheniramine maleate)
Trial: 30136858
Drug: General daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General daily lifestyle intervention
Trial: 26598919
Drug: Kan Jang
RxNorm normalized name: ASIAN GINSENG 500 mg in 500 mg ORAL CAPSULE [Cheong-Kwan-Jang Korean HongSam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kan Jang (KJ) oral solution (30 ml/day; 762 mg genuine extracts with standardized contents of 0.2 mg/ml vasicine, 0.8 mg/ml chicoric acid, and 0.03 mg/ml eleutherosides B and E)
Trial: 26598919
Drug: Bromhexine hydrochloride
RxNorm normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine hydrochloride (24 mg/30 ml/day)
Trial: 17080004
Drug: 8 vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 vs. 15 days of antibiotics
Trial: 2094341
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms selenium daily for 14 days
Trial: 639229
Drug: Propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.1 mg/kg intravenously followed by 320 mg orally over 27 hours)
Trial: 22773237
Drug: liver suspension
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liver suspension tape
Trial: 22773237
Drug: V‐shaped liver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V‐shaped liver suspension technique (V‐LIST)
Trial: 11994337
Drug: 0.27 mg/kg.wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.27 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Trial: 11994337
Drug: 0.27 mg/kg.wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.27 mg/kg.wk of recombinant human GH with oral placebo
Trial: 11994337
Drug: 0.36 mg/kg.wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.36 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Trial: 11994337
Drug: 0.36 mg/kg.wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.36 mg/kg.wk of recombinant human GH with oral placebo
Trial: 11994337
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of estrogen (low doses)
Trial: 7702820
Drug: Polymyxin B‐neomycin‐hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B‐neomycin‐hydrocortisone drops (single dose intraoperatively)
Trial: 31300667
Drug: Micronutrient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient treatment
Trial: 27170530
Drug: Condensed regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condensed regimen (100 mg twice daily for 2 weeks followed by 200 mg twice daily)
Trial: 27170530
Drug: Conservative regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative regimen (50 mg twice daily for 2 weeks, 100 mg twice daily for 3 weeks, followed by 200 mg twice daily)
Trial: 27170530
Drug: High-dose ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ACEI/ARB with condensed regimen
Trial: 22813494
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with propofol infusion stopped and remifentanil infusion also stopped during ventilator weaning
Trial: 20571327
Drug: Multifactor approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactor approach (cognitive‐behavioral therapies, diet and physical activity counselling, 'on‐off' prescription of orlistat)
Trial: 12099782
Drug: Oral pizotifen
RxNorm normalized name: pizotifen
DrugBank: Pizotifen (DB06153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pizotifen